REATA TO BEGIN TESTING RTA 402

A A

Reata Pharmaceuticals has reported that its third development candidate, RTA 402, has received FDA clearance to begin clinical testing in patients with solid tumors, lymphoma, and myeloma. A clinical trial has been initiated with this agent at the M. D. Anderson Cancer Center in Houston, Texas.

RTA 402 is a novel targeted cancer therapy with a unique mechanism of action. It exploits fundamental physiological differences between cancerous and noncancerous cells by modulating oxidative stress response pathways. As a result, the drug is toxic to cancer cells but induces protective antioxidant and anti-inflammatory responses in normal cells.